Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease.

Abhik Bhattacharya,Daniel Travis,Mark T Osterman,James D Lewis,Bhavana Bhagya Rao,Helen Lee,Gary R Lichtenstein

Journal of clinical gastroenterology（2023）

引用 5|浏览16

暂无评分

摘要

In this large CD cohort, there was no association between infliximab TL and risk of short-term IC or NIC. Interestingly, a shorter duration of exposure predicted higher rates of IC. This supports the safety of targeting higher infliximab TLs when necessary and greater vigilance during the early stages of treatment.

查看译文

关键词

therapeutic drug monitoring,complications,infliximab,Crohn's disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要